Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
Nat Med. 2024 Apr 23. doi: 10.1038/s41591-024-02942-7. Online ahead of print.
Nat Med. 2024.
PMID: 38653864
Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity.
Brodeur MN, Dopeso H, Zhu Y, Longhini ALF, Gazzo A, Sun S, Koche R, Qu R, Hamard PJ, Bykov Y, Green H, Chiappinelli KB, Ozsoy MA, Basili T, Gardner R, Walderich S, DeStanchina E, Greenbaum B, Gönen M, Weigelt B, Zamarin D.
Brodeur MN, et al. Among authors: ozsoy ma.
bioRxiv [Preprint]. 2023 Aug 11:2023.08.08.552544. doi: 10.1101/2023.08.08.552544.
bioRxiv. 2023.
PMID: 37609261
Free PMC article.
Preprint.
Item in Clipboard
Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathways.
James NE, Woodman M, De La Cruz P, Eurich K, Ozsoy MA, Schorl C, Hanley LC, Ribeiro JR.
James NE, et al. Among authors: ozsoy ma.
Front Immunol. 2022 Sep 5;13:965331. doi: 10.3389/fimmu.2022.965331. eCollection 2022.
Front Immunol. 2022.
PMID: 36131935
Free PMC article.
Item in Clipboard
Cite
Cite